



ULCERATIVE COLITIS AGENTS PRIOR AUTHORIZATION FORM (form effective 1/5/2026)

Prior authorization guidelines for **Ulcerative Colitis Agents** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <https://www.pa.gov/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services>.

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		total pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:		NPI:	State license #:	
LTC facility contact/phone:		Street address:		
Beneficiary name:		City/state/zip:		
Beneficiary ID#:	DOB:	Phone:	Fax:	

CLINICAL INFORMATION

Drug requested:	Dosage form:	Strength:	
Directions:		Quantity:	Refills:
Diagnosis (<i>submit documentation</i>):		Dx code (<i>required</i>):	
Is the beneficiary currently being treated with the requested medication?	<input type="checkbox"/> Yes – date of last dose: _____ <i>Submit documentation.</i> <input type="checkbox"/> No		

Complete all sections that apply to the beneficiary and this request.
Check all that apply and submit documentation for each item.

INITIAL requests

- For a SPHINGOSINE 1-PHOSPHATE RECEPTOR (S1PR) MODULATOR (eg, VELSIPITY [etrasimod], ZEPOSIA [ozanimod]) for treatment of ulcerative colitis (UC):
 - Is prescribed the drug by or in consultation with an appropriate specialist (eg, a gastroenterologist)
 - Has moderate-to-severe UC
 - Has UC associated with multiple poor prognostic factors
 - Has achieved remission with the requested medication AND:
 - Will be using the requested medication as maintenance therapy to maintain remission
 - Tried and failed or has a contraindication or an intolerance to the preferred Cytokine and CAM Antagonists that are FDA-approved or medically accepted for the treatment of UC. (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred Cytokine and CAM Antagonists.)



Request is for **VELSIPITY (etrasimod) AND:**

Has a comorbid heart condition – describe: _____

Experienced any of the following in the past 6 months:

- | | |
|--|--|
| <input type="checkbox"/> Myocardial infarction | <input type="checkbox"/> Transient ischemic attack |
| <input type="checkbox"/> Unstable angina | <input type="checkbox"/> Decompensated heart failure requiring hospitalization |
| <input type="checkbox"/> Stroke | <input type="checkbox"/> Class III or IV heart failure |

Request is for **ZEPOSIA (ozanimod) AND:**

Has severe untreated sleep apnea

Will be taking a monoamine oxidase (MAO) inhibitor while taking Zeposia (e.g., selegiline, phenelzine)

Has a comorbid heart condition – describe: _____

Experienced any of the following in the past 6 months:

- | | |
|--|--|
| <input type="checkbox"/> Myocardial infarction | <input type="checkbox"/> Transient ischemic attack |
| <input type="checkbox"/> Unstable angina | <input type="checkbox"/> Decompensated heart failure requiring hospitalization |
| <input type="checkbox"/> Stroke | <input type="checkbox"/> Class III or IV heart failure |

2. For all other NON-PREFERRED Ulcerative Colitis Agents:

Tried and failed or has a contraindication or an intolerance to the preferred Ulcerative Colitis Agents (*Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.*)

RENEWAL requests

1. For a SPHINGOSINE 1-PHOSPHATE RECEPTOR (S1PR) MODULATOR (eg, VELSIPITY [etrasimod], ZEPOSIA [ozanimod]):

- Is prescribed the medication by or in consultation with an appropriate specialist (eg, a gastroenterologist)
- Experienced improvement in disease activity or level of functioning since starting the requested medication

Request is for **VELSIPITY (etrasimod) AND:**

Has a comorbid heart condition – describe: _____

Experienced any of the following in the past 6 months:

- | | |
|--|--|
| <input type="checkbox"/> Myocardial infarction | <input type="checkbox"/> Transient ischemic attack |
| <input type="checkbox"/> Unstable angina | <input type="checkbox"/> Decompensated heart failure requiring hospitalization |
| <input type="checkbox"/> Stroke | <input type="checkbox"/> Class III or IV heart failure |

Request is for **ZEPOSIA (ozanimod) AND:**

Has severe untreated sleep apnea

Will be taking a monoamine oxidase inhibitor while taking Zeposia (e.g., selegiline, phenelzine)

Has a comorbid heart condition – describe: _____

Experienced any of the following in the past 6 months:

- | | |
|--|--|
| <input type="checkbox"/> Myocardial infarction | <input type="checkbox"/> Transient ischemic attack |
| <input type="checkbox"/> Unstable angina | <input type="checkbox"/> Decompensated heart failure requiring hospitalization |
| <input type="checkbox"/> Stroke | <input type="checkbox"/> Class III or IV heart failure |

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:

Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.